López-Sánchez, Noelia http://orcid.org/0000-0003-3095-3438
Ramón-Landreau, Morgan http://orcid.org/0000-0002-2672-116X
Trujillo, Cristina
Garrido-García, Alberto http://orcid.org/0000-0002-4214-1990
Frade, José M. http://orcid.org/0000-0001-7067-2505
Funding for this research was provided by:
Consejo Superior de Investigaciones Cientificas
Article History
Received: 15 December 2021
Accepted: 28 January 2022
First Online: 7 March 2022
Declarations
:
: Procedures have been approved by the Scientific Committee of BT-CIEN and the Bioethics Committee of CSIC.
: Written informed consent for brain removal after death for diagnostic and research purposes was obtained from brain donors and/or next of kin.
: Not applicable
: J. M. F. is a shareholder (7.16% equity ownership) of Tetraneuron, a biotech company exploiting his patent on the blockade of NT by E2F4DN as a therapeutic approach against AD. N. L. S. received her salary from a R&D contract with Tetraneuron, and currently, she works for this biotech company. M. R. L. and A. G. G. work for Tetraneuron.